<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02713464</url>
  </required_header>
  <id_info>
    <org_study_id>SKIN1</org_study_id>
    <nct_id>NCT02713464</nct_id>
  </id_info>
  <brief_title>Does Maternal Instruction Prevent Kernicterus in Nigeria?</brief_title>
  <official_title>Effect of Education on Prevalence of Kernicterus in Five Regions in Nigeria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bilimetrix s.r.l.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jos University Teaching Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayern University Teaching Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ahmadu Bello University Teaching Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massey Street Childrens Hospital Lagos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal Medical Center Asaba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bilimetrix s.r.l.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines (a) whether introduction of public, health provider, and maternal
      education about risks of jaundice will decrease the occurrence of ABE compared with baseline
      prevalence (before-after design) or (b) whether antenatal or postpartum instruction to
      mothers will decrease the incidence of ABE compared with those who did not received
      instruction (concurrent opportunistic controls in phase 2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This 2 phase study first determines the prevalence of acute bilirubin encephalopathy (ABE)
      among newborns admitted for treatment of jaundice at 5 regional centers in Nigeria and
      identifies social/behavioral/medical factors associated with ABE. Information gained in phase
      1 identified high risk sub-populations and guided selection of instructional materials for
      phase 2. Core data sheets submitted monthly by participating centers included clinical data,
      demographic information, number of antenatal clinic visits, birth place (hospital, clinic,
      home) and attendant, distance from care centers and reasons for delay, if any, in seeking
      care. Receipt of jaundice instruction by mothers is self-reported. Statistical analysis
      includes Chi square and logistic regression analysis of risk factors. Sample size: 1,000
      subjects in each phase are required to demonstrate a 20% decrease in disease prevalence
      (baseline ABE incidence anticipated to be 15% of jaundiced babies) at 95% confidence level.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute bilirubin encephalopathy</measure>
    <time_frame>at time of admission or discharge (1-21 days of life)</time_frame>
    <description>Clinical signs of bilirubin toxicity described by unique neurological features in the presence of hyperbilirubinemia: reported as yes, no, or suspect (mild signs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death from acute bilirubin encephalopathy or combined ABE/sepsis</measure>
    <time_frame>1-21 days of life</time_frame>
    <description>Clinical signs of severe bilirubin toxicity with or without clinical signs of sepsis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1765</enrollment>
  <condition>Kernicterus</condition>
  <arm_group>
    <arm_group_label>maternal education</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phase IIa: Pregnant women attending antenatal clinics or postpartum in clinics or hospital who receive programmed maternal education about risks and care of newborn jaundice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Historic control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Phase I: (before-after design) Baseline prevalence of acute bilirubin encephalopathy before maternal education instituted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Phase IIb: Opportunistic controls - infants of mothers who failed to receive education about risks and care of newborn jaundice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>maternal education</intervention_name>
    <description>Antenatal and/or postpartum Instruction on risks of neonatal jaundice, dangerous practices, technique to evaluate jaundice, early signs of ABE, when to seek care.</description>
    <arm_group_label>maternal education</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newborn infant receiving treatment for neonatal jaundice

        Exclusion Criteria:

          -  Non-viable premature infants

          -  Severe congenital defects.

          -  Postnatal age greater than 21 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Oguche, MBBS</last_name>
    <role>Study Director</role>
    <affiliation>Jos University Teaching Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abieyuwa Emokpae, MBBS</last_name>
    <role>Study Director</role>
    <affiliation>Massey Street Pediatric Hospital, Lagos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zubaida Farouk, MBBS</last_name>
    <role>Study Director</role>
    <affiliation>Aminu Kano Teaching Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angela Okolo, MBBS</last_name>
    <role>Study Director</role>
    <affiliation>Federal Medical Center Asaba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isa Abdulkadir, MBBS</last_name>
    <role>Study Director</role>
    <affiliation>Ahmadu Bello University Teaching Hospital</affiliation>
  </overall_official>
  <results_reference>
    <citation>Johnson L, Bhutani VK, Karp K, Sivieri EM, Shapiro SM. Clinical report from the pilot USA Kernicterus Registry (1992 to 2004). J Perinatol. 2009 Feb;29 Suppl 1:S25-45. doi: 10.1038/jp.2008.211.</citation>
    <PMID>19177057</PMID>
  </results_reference>
  <results_reference>
    <citation>Shapiro SM. Chronic bilirubin encephalopathy: diagnosis and outcome. Semin Fetal Neonatal Med. 2010 Jun;15(3):157-63. doi: 10.1016/j.siny.2009.12.004. Epub 2010 Jan 29. Review.</citation>
    <PMID>20116355</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2016</study_first_submitted>
  <study_first_submitted_qc>March 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <last_update_submitted>March 17, 2016</last_update_submitted>
  <last_update_submitted_qc>March 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bilimetrix s.r.l.</investigator_affiliation>
    <investigator_full_name>Richard Patridge Wennberg</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kernicterus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

